

COLUMBIA LABORATORIES INC

Form 4/A

March 12, 2014

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Actavis plc

2. Issuer Name **and** Ticker or Trading
Symbol
COLUMBIA LABORATORIES
INC [CBRX]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction
(Month/Day/Year)
03/07/2014

____ Director ____X____ 10% Owner
____ Officer (give title below) ____ Other (specify below)

C/O ACTAVIS CHIEF LEGAL
OFFICER, MORRIS CORP CTR III,
400 INTERPACE PKWY

(Street)

4. If Amendment, Date Original
Filed(Month/Day/Year)
03/11/2014

6. Individual or Joint/Group Filing(Check
Applicable Line)
____ Form filed by One Reporting Person
X Form filed by More than One Reporting
Person

PARSIPPANY, NJ 07054

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/07/2014		S	1,400,000 (1)	\$ 6.0779 (3)	0	I (2) See Footnote (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form
displays a currently valid OMB control
number.**

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Benef Own Follo Repor Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Actavis plc C/O ACTAVIS CHIEF LEGAL OFFICER MORRIS CORP CTR III, 400 INTERPACE PKWY PARSIPPANY, NJ 07054			X	
COVENTRY ACQUISITION, LLC C/O ACTAVIS CHIEF LEGAL COUNSEL MORRIS CORP CTR III, 400 INTERPACE PKWY PARSIPPANY, NJ 07054			X	

Signatures

/s/ David A. Buchen, Chief Legal Officer - Global and Secretary of Actavis
plc 03/12/2014

__Signature of Reporting Person

Date

/s/ David A. Buchen, General Counsel and Secretary of Coventry Acquisition,
LLC 03/12/2014

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The shares reported herein reflect the 1-for-8 reverse stock split of the Issuer's common stock which took effect on August 9, 2013.

(2) Coventry Acquisition LLC, the direct record holder of the shares reported herein, is an indirect subsidiary of Actavis plc.

(3) This amendment to Form 4 is being filed solely to correct the price per share amount in Column 4 from \$5.76 to \$6.0779.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Edgar Filing: COLUMBIA LABORATORIES INC - Form 4/A

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.